Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO EBITDA Margin
EBITDA as a percentage of revenue.
Bio-Rad Laboratories, Inc.NYSE: BIO
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 83.3%
EBITDA Margin was 83.3% in Q2 FY2026, up 11.6 pp from a year earlier. On a trailing-twelve-month basis it was 19.9%, down 6.2 pp year over year. Over 3 fiscal years it widened by 208.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 21.7% for the fiscal year ending Dec 2026, down from 46.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 83.3%+190.8 pp QoQ
- Last fiscal yearDec 2025
- 46.8%+130.3 pp YoY
- LTMJun 2026
- 19.9%-6.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 46.8%
- Year-over-year change
- +130.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.8% | +130.3pp |
| FY2024 | 2024-12-31 | -83.5% | -58.9pp |
| FY2023 | 2023-12-31 | -24.5% | +137.1pp |
| FY2022 | 2022-12-31 | -161.6% | -352.8pp |
| FY2021 | 2021-12-31 | 191.2% | — |
EBITDA Margin vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 EBITDA Margin of 19.9% is the 6th highest of the 11 companies compared; the peer median is 14.7%.
- Its year-over-year change of -6.2 pp is the 9th highest of 11, against a peer median of -1.4 pp.
- Over three fiscal years its change of +208.5 pp compares with a peer median of -9.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 27.7% | -0.6 pp | -7.3 pp | |
| LTM Sep 2026 | 26.8% | +8.6 pp | -11.9 pp | |
| LTM Jul 2026 | 26.3% | -3.0 pp | -8.9 pp | |
| LTM Sep 2026 | 23.7% | -2.2 pp | -0.9 pp | |
| LTM Jun 2026 | 22.3% | +5.6 pp | -9.9 pp | |
| LTM Jun 2026 | 19.9% | -6.2 pp | +208.5 pp | |
| LTM Jun 2026 | 7.1% | -4.6 pp | -11.7 pp | |
| LTM Sep 2026 | -15.2% | -24.8 pp | -32.6 pp | |
| LTM Jun 2026 | -26.6% | +89.9 pp | -148.5 pp | |
| LTM Mar 2026 | -66.6% | +85.7 pp | +198.6 pp | |
| LTM Mar 2026 | -94.5% | -30.2 pp | +72.1 pp | |
| Peer median (excluding BIO) | 14.7% | -1.4 pp | -9.4 pp | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Gross Margin | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| Research & Development | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M |
| Selling, General & Admin | 877.12M | 827.83M | 841.7M | 814M | 819.9M |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| EBITDA | 5.59B | (4.53B) | (654.8M) | (2.14B) | 1.21B |
| EBITDA Margin | 191.2% | -161.6% | -24.5% | -83.5% | 46.8% |
| Operating Income | 500.34M | 482.62M | 337.8M | 269M | 270.5M |
| Operating Margin | 17.1% | 17.2% | 12.6% | 10.5% | 10.5% |
| Interest Income | 18.9M | 58M | 100.9M | 82M | 95.5M |
| Interest Expense | 1.55M | 38.11M | 49.44M | 48.9M | 49M |
| Other Income / Expenses | 4.95B | (5.19B) | (1.19B) | (2.61B) | 725M |
| Income Before Tax | 5.45B | (4.7B) | (850.1M) | (2.34B) | 995.5M |
| Pre-Tax Margin | 186.4% | -167.9% | -31.8% | -91.3% | 38.5% |
| Income Tax Expense | 1.19B | (1.08B) | (212.78M) | (498.3M) | 235.6M |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.9M |
| Net Margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (Basic) | 142.61 | (121.79) | (21.82) | (65.36) | 27.87 |
| EPS (Diluted) | 140.83 | (121.79) | (21.82) | (65.36) | 27.87 |
| Weighted Avg Shares | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M |
| Weighted Avg Shares (Diluted) | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.